CLSA ON PHARMA : Maintains Buy on Sun Pharma, Lupin,  Torrent Pharma & Glenmark

CLSA ON PHARMA : Maintains Outperform on Cadila Health; Underperform on DRL, Cipla

CLSA ON PHARMA : Maintains Sell on IPCA Labs & Biocon

CLSA ON PHARMA : Sun Pharma to lead earnings growth  recovery for H2FY16

CLSA ON PHARMA : Cipla should witness muted growth due to its on-going investment phase

CLSA ON PHARMA : Cadila may have downside risk on delay  of gAsacol HD launch

CLSA ON PHARMA : Torrent Pharma will benefit from  contribution from gAbilify,gNexium in US.

CLSA ON PHARMA : gGlumetza's US launch & recent portfolio rationalisation benefits to aid Lupin

CLSA ON PHARMA : DRL expected to witness PAT growth due to strong US sales for injectable pdts

CLSA ON BHARAT FORGE : Maintains Sell; target of ₹745

BofA ML:BHARAT FORGE : Maintains Underperform; cuts target to ₹650 from ₹740

BofA ML:BHARAT FORGE : Bharat Forge management guided to flat  sales in FY16

CS ON INDIA : 2015 saw broader indices outperforming  narrower ones across sectors

CS ON INDIA : Believe global linkages hurt large caps  on high FII ownership

CS ON INDIA : Domestic economy remains relatively more robust as evident in eco indicators

CS ON INDIA : Stay Overweight on consumption; Underweight on financials

CS ON INDIA : Bullish on Tech Mahindra, HUL, Ultratech & Tata Motors

CS ON INDIA : Recommend trimming positions in SBI  & Bharti Airtel

MS ON UNITED SPIRITS : Maintains Overweight; cuts target to  ₹3,950 from ₹4,855

CITI ON PIRAMAL ENT : Maintains Neutral; raises target to  ₹1,010 from ₹595

CLSA ON BHARAT FORGE : Mgmt acknowledged near-term cyclical  pressures in US CVs & industrial exports

CLSA ON BHARAT FORGE : Management now expects standalone  revenues to remain flat YoY in FY16

CLSA ON BHARAT FORGE : Tentative on achieving its FY18  standalone top-line target of ₹7,000 cr

CLSA ON BHARAT FORGE : Cyclical slowdown in key end segments  to overshadow growth over next 1-2 yrs